Adenoviral vector-mediated gene therapy for gliomas: coming of age

Bibliography

• Fisher JL, Schwartzbaum JA, Wrensch M, et al. Epidemiology of brain tumors. Neurol Clin 2007;25:867-90; vii
   PubMed Web of Science ®Google Scholar
• Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10:459-66
   PubMed Web of Science ®Google Scholar
• Rux JJ, Burnett RM. Adenovirus structure. Hum Gene Ther 2004;15:1167-76
   PubMed Web of Science ®Google Scholar
• Volpers C, Kochanek S. Adenoviral vectors for gene transfer and therapy. J Gene Med 2004;6(Suppl 1):S164-71
   PubMed Web of Science ®Google Scholar
• Bergelson JM, Cunningham JA, Droguett G, et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997;275:1320-3
   PubMed Web of Science ®Google Scholar
• Zhang Y, Bergelson JM. Adenovirus receptors. J Virol 2005;79:12125-31
   PubMed Web of Science ®Google Scholar
• Hong SS, Karayan L, Tournier J, et al. Adenovirus type 5 fiber knob binds to MHC class I alpha2 domain at the surface of human epithelial and B lymphoblastoid cells. Embo J 1997;16:2294-306
   PubMed Web of Science ®Google Scholar
• Lowenstein PR, Thomas CE, Umana P, et al. High-capacity, helper-dependent, "gutless" adenoviral vectors for gene transfer into brain. Methods Enzymol 2002;346:292-311
   PubMed Web of Science ®Google Scholar
• Zirger JM, Puntel M, Bergeron J, et al. Immune-mediated loss of transgene expression from virally transduced brain cells is irreversible, mediated by IFNgamma, perforin, and TNFalpha, and due to the elimination of transduced cells. Mol Ther 2012;20:808-19
   Google Scholar
• Puntel M, Barrett R, Sanderson NS, et al. Identification and visualization of CD8+ T cell mediated IFN-gamma signaling in target cells during an antiviral immune response in the brain. PLoS One 2011;6:e23523
   PubMedGoogle Scholar
• Barcia C, Gerdes C, Xiong WD, et al. Immunological thresholds in neurological gene therapy: highly efficient elimination of transduced cells might be related to the specific formation of immunological synapses between T cells and virus-infected brain cells. Neuron Glia Biol 2006;2:309-22
   PubMed Web of Science ®Google Scholar
• Lowenstein PR, Mandel RJ, Xiong WD, et al. Immune responses to adenovirus and adeno-associated vectors used for gene therapy of brain diseases: the role of immunological synapses in understanding the cell biology of neuroimmune interactions. Curr Gene Ther 2007;7:347-60
   PubMed Web of Science ®Google Scholar
• Barcia C, Jimenez-Dalmaroni M, Kroeger KM, et al. One-year expression from high-capacity adenoviral vectors in the brains of animals with pre-existing anti-adenoviral immunity: clinical implications. Mol Ther 2007;15:2154-63
   PubMed Web of Science ®Google Scholar
• Thomas CE, Schiedner G, Kochanek S, et al. Preexisting antiadenoviral immunity is not a barrier to efficient and stable transduction of the brain, mediated by novel high-capacity adenovirus vectors. Hum Gene Ther 2001;12:839-46
   PubMed Web of Science ®Google Scholar
• Thomas CE, Schiedner G, Kochanek S, et al. Peripheral infection with adenovirus causes unexpected long-term brain inflammation in animals injected intracranially with first-generation, but not with high-capacity, adenovirus vectors: toward realistic long-term neurological gene therapy for chronic diseases. Proc Natl Acad Sci USA 2000;97:7482-7
   PubMed Web of Science ®Google Scholar
• Kochanek S. High-capacity adenoviral vectors for gene transfer and somatic gene therapy. Hum Gene Ther 1999;10:2451-9
   PubMed Web of Science ®Google Scholar
• Lowenstein PR, Castro MG. Genetic engineering within the adult brain: implications for molecular approaches to behavioral neuroscience. Physiol Behav 2001;73:833-9
   PubMed Web of Science ®Google Scholar
• Xiong W, Goverdhana S, Sciascia SA, et al. Regulatable gutless adenovirus vectors sustain inducible transgene expression in the brain in the presence of an immune response against adenoviruses. J Virol 2006;80:27-37
   PubMed Web of Science ®Google Scholar
• VanderVeen N, Paran C, Krasinkiewicz J, et al. Effectiveness and preclinical safety profile of doxycycline to be used "off-label" to induce therapeutic transgene expression in a phase I clinical trial for glioma. Hum Gene Ther Clin Dev 2013;24:116-26
   Google Scholar
• Muhammad AK, Puntel M, Candolfi M, et al. Study of the efficacy, biodistribution, and safety profile of therapeutic gutless adenovirus vectors as a prelude to a phase I clinical trial for glioblastoma. Clin Pharmacol Ther 2010;88:204-13
   PubMed Web of Science ®Google Scholar
• Puntel M, Muhammad AKMG, Farrokhi C, et al. Safety profile, efficacy, and biodistribution of a bicistronic high-capacity adenovirus vector encoding a combined immunostimulation and cytotoxic gene therapy as a prelude to a phase I clinical trial for glioblastoma. Toxicol Appl Pharmacol 2013;268:318-30
   PubMed Web of Science ®Google Scholar
• Rodriguez R, Schuur ER, Lim HY, et al. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res 1997;57: 2559-63
   Google Scholar
• Sonabend AM, Ulasov IV, Tyler MA, et al. Mesenchymal stem cells effectively deliver an oncolytic adenovirus to intracranial glioma. Stem Cells 2008;26:831-41
   PubMed Web of Science ®Google Scholar
• Fueyo J, Gomez-Manzano C, Alemany R, et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 2000;19:2-12
   PubMed Web of Science ®Google Scholar
• Gomez-Manzano C, Yung WK, Alemany R, et al. Genetically modified adenoviruses against gliomas: from bench to bedside. Neurology 2004;63:418-26
   PubMed Web of Science ®Google Scholar
• Harada JN, Berk AJ. p53-Independent and -dependent requirements for E1B-55K in adenovirus type 5 replication. J Virol 1999;73:5333-44
   PubMed Web of Science ®Google Scholar
• O'Shea CC, Johnson L, Bagus B, et al. Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell 2004;6:611-23
   PubMed Web of Science ®Google Scholar
• Suzuki K, Fueyo J, Krasnykh V, et al. A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency. Clin Cancer Res 2001;7:120-6
   PubMed Web of Science ®Google Scholar
• Dmitriev I, Krasnykh V, Miller CR, et al. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 1998;72:9706-13
   PubMed Web of Science ®Google Scholar
• Lamfers ML, Idema S, Bosscher L, et al. Differential effects of combined Ad5-delta 24RGD and radiation therapy in in vitro versus in vivo models of malignant glioma. Clin Cancer Res 2007;13:7451-8
   PubMed Web of Science ®Google Scholar
• Hemminki O, Bauerschmitz G, Hemmi S, et al. Oncolytic adenovirus based on serotype 3. Cancer Gene Ther 2011;18:288-96
   PubMed Web of Science ®Google Scholar
• Yu W, Fang H. Clinical trials with oncolytic adenovirus in China. Curr Cancer Drug Targets 2007;7:141-8
   PubMed Web of Science ®Google Scholar
• Moolten FL. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res 1986;46:5276-81
   PubMed Web of Science ®Google Scholar
• Kurozumi K, Tamiya T, Ono Y, et al. Apoptosis induction with 5-fluorocytosine/cytosine deaminase gene therapy for human malignant glioma cells mediated by adenovirus. J Neurooncol 2004;66:117-27
   PubMed Web of Science ®Google Scholar
• Dachs GU, Tupper J, Tozer GM. From bench to bedside for gene-directed enzyme prodrug therapy of cancer. Anticancer Drugs 2005;16:349-59
   PubMed Web of Science ®Google Scholar
• Gadi VK, Alexander SD, Waud WR, et al. A long-acting suicide gene toxin, 6-methylpurine, inhibits slow growing tumors after a single administration. J Pharmacol Exp Ther 2003;304:1280-4
   PubMed Web of Science ®Google Scholar
• Springer CJ, Niculescu-Duvaz I. Prodrug-activating systems in suicide gene therapy. J Clin Invest 2000;105:1161-7
   PubMed Web of Science ®Google Scholar
• Maatta AM, Samaranayake H, Pikkarainen J, et al. Adenovirus mediated herpes simplex virus-thymidine kinase/ganciclovir gene therapy for resectable malignant glioma. Curr Gene Ther 2009;9:356-67
   PubMed Web of Science ®Google Scholar
• Kokoris MS, Black ME. Characterization of herpes simplex virus type 1 thymidine kinase mutants engineered for improved ganciclovir or acyclovir activity. Protein Sci 2002;11:2267-72
   PubMed Web of Science ®Google Scholar
• Mineharu Y, Muhammad AK, Yagiz K, et al. Gene therapy-mediated reprogramming tumor infiltrating T cells using IL-2 and inhibiting NF-kappaB signaling improves the efficacy of immunotherapy in a brain cancer model. Neurotherapeutics 2012;9:827-43
   PubMed Web of Science ®Google Scholar
• Black ME, Kokoris MS, Sabo P. Herpes simplex virus-1 thymidine kinase mutants created by semi-random sequence mutagenesis improve prodrug-mediated tumor cell killing. Cancer Res 2001;61:3022-6
   PubMed Web of Science ®Google Scholar
• Khan Z, Knecht W, Willer M, et al. Plant thymidine kinase 1: a novel efficient suicide gene for malignant glioma therapy. Neuro Oncol 2010;12:549-58
   PubMed Web of Science ®Google Scholar
• Valerie K, Brust D, Farnsworth J, et al. Improved radiosensitization of rat glioma cells with adenovirus-expressed mutant herpes simplex virus-thymidine kinase in combination with acyclovir. Cancer Gene Ther 2000;7:879-84
   PubMed Web of Science ®Google Scholar
• Nestler U, Wakimoto H, Siller-Lopez F, et al. The combination of adenoviral HSV TK gene therapy and radiation is effective in athymic mouse glioblastoma xenografts without increasing toxic side effects. J Neurooncol 2004;67:177-88
   PubMed Web of Science ®Google Scholar
• Chiocca EA, Aguilar LK, Bell SD, et al. Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma. J Clin Oncol 2011;29:3611-19
   PubMed Web of Science ®Google Scholar
• Keyvani K, Baur I, Paulus W. Tetracycline-controlled expression but not toxicity of an attenuated diphtheria toxin mutant. Life Sci 1999;64:1719-24
   PubMed Web of Science ®Google Scholar
• Paulus W, Baur I, Oberer DM, et al. Regulated expression of the diphtheria toxin A gene in human glioma cells using prokaryotic transcriptional control elements. J Neurosurg 1997;87:89-95
   PubMed Web of Science ®Google Scholar
• Curtin JF, Candolfi M, Xiong W, et al. Turning the gene tap off; implications of regulating gene expression for cancer therapeutics. Mol Cancer Ther 2008;7:439-48
   PubMed Web of Science ®Google Scholar
• Debinski W, Gibo DM. Molecular expression analysis of restrictive receptor for interleukin 13, a brain tumor-associated cancer/testis antigen. Mol Med 2000;6:440-9
   PubMed Web of Science ®Google Scholar
• Debinski W, Obiri NI, Pastan I, et al. A novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin is highly cytotoxic to human carcinoma cells expressing receptors for interleukin 13 and interleukin 4. J Biol Chem 1995;270:16775-80
   PubMed Web of Science ®Google Scholar
• Kunwar S, Prados MD, Chang SM, et al. Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J Clin Oncol 2007;25:837-44
   PubMed Web of Science ®Google Scholar
• Liu H, Prayson RA, Estes ML, et al. In vivo expression of the interleukin 4 receptor alpha by astrocytes in epilepsy cerebral cortex. Cytokine 2000;12:1656-61
   PubMed Web of Science ®Google Scholar
• Candolfi M, Xiong W, Yagiz K, et al. Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics. Proc Natl Acad Sci USA 2010;107:20021-6
   PubMed Web of Science ®Google Scholar
• Kawakami K, Kawakami M, Kioi M, et al. Distribution kinetics of targeted cytotoxin in glioma by bolus or convection-enhanced delivery in a murine model. J Neurosurg 2004;101:1004-11
   PubMed Web of Science ®Google Scholar
• Mintz A, Gibo DM, Madhankumar AB, et al. Molecular targeting with recombinant cytotoxins of interleukin-13 receptor alpha2-expressing glioma. J Neurooncol 2003;64:117-23
   PubMed Web of Science ®Google Scholar
• Debinski W, Gibo DM, Obiri NI, et al. Novel anti-brain tumor cytotoxins specific for cancer cells. Nat Biotechnol 1998;16:449-53
   PubMed Web of Science ®Google Scholar
• Madhankumar AB, Mintz A, Debinski W. Interleukin 13 mutants of enhanced avidity toward the glioma-associated receptor, IL13Ralpha2. Neoplasia 2004;6:15-22
   PubMed Web of Science ®Google Scholar
• Curtin JF, King GD, Barcia C, et al. Fms-like tyrosine kinase 3 ligand recruits plasmacytoid dendritic cells to the brain. J Immunol 2006;176:3566-77
   PubMed Web of Science ®Google Scholar
• Sanchez-Perez L, Choi BD, Reap EA, et al. BLyS levels correlate with vaccine-induced antibody titers in patients with glioblastoma lymphodepleted by therapeutic temozolomide. Cancer Immunol Immunother 2013;62:983-7
   PubMed Web of Science ®Google Scholar
• Maraskovsky E, Brasel K, Teepe M, et al. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J Exp Med 1996;184:1953-62
   PubMed Web of Science ®Google Scholar
• Chakravarty PK, Alfieri A, Thomas EK, et al. Flt3-ligand administration after radiation therapy prolongs survival in a murine model of metastatic lung cancer. Cancer Res 1999;59:6028-32
   PubMed Web of Science ®Google Scholar
• Chen K, Braun S, Lyman S, et al. Antitumor activity and immunotherapeutic properties of Flt3-ligand in a murine breast cancer model. Cancer Res 1997;57:3511-16
   PubMed Web of Science ®Google Scholar
• Somers KD, Brown RR, Holterman DA, et al. Orthotopic treatment model of prostate cancer and metastasis in the immunocompetent mouse: efficacy of flt3 ligand immunotherapy. Int J Cancer 2003;107:773-80
   PubMed Web of Science ®Google Scholar
• Candolfi M, Yagiz K, Foulad D, et al. Release of HMGB1 in response to proapoptotic glioma killing strategies: efficacy and neurotoxicity. Clin Cancer Res 2009;15:4401-14
   PubMed Web of Science ®Google Scholar
• Curtin JF, Liu N, Candolfi M, et al. HMGB1 mediates endogenous TLR2 activation and brain tumor regression. PLoS Med 2009;6:e10
   PubMed Web of Science ®Google Scholar
• Ghulam Muhammad AK, Candolfi M, King GD, et al. Antiglioma immunological memory in response to conditional cytotoxic/immune-stimulatory gene therapy: humoral and cellular immunity lead to tumor regression. Clin Cancer Res 2009;15:6113-27
   PubMed Web of Science ®Google Scholar
• Candolfi M, Yagiz K, Wibowo M, et al. Temozolomide does not impair gene therapy-mediated antitumor immunity in syngeneic brain tumor models. Clin Cancer Res 2014;20:1555-65
   PubMed Web of Science ®Google Scholar
• Ali S, Curtin JF, Zirger JM, et al. Inflammatory and anti-glioma effects of an adenovirus expressing human soluble Fms-like tyrosine kinase 3 ligand (hsFlt3L): treatment with hsFlt3L inhibits intracranial glioma progression. Mol Ther 2004;10:1071-84
   PubMed Web of Science ®Google Scholar
• Tada Y, O-Wang J, Yu L, et al. T-cell-dependent antitumor effects produced by CD40 ligand expressed on mouse lung carcinoma cells are linked with the maturation of dendritic cells and secretion of a variety of cytokines. Cancer Gene Ther 2003;10:451-6
   PubMed Web of Science ®Google Scholar
• Peter I, Nawrath M, Kamarashev J, et al. Immunotherapy for murine K1735 melanoma: combinatorial use of recombinant adenovirus expressing CD40L and other immunomodulators. Cancer Gene Ther 2002;9:597-605
   PubMed Web of Science ®Google Scholar
• Kaplan DH, Shankaran V, Dighe AS, et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 1998;95:7556-61
   PubMed Web of Science ®Google Scholar
• Street SE, Cretney E, Smyth MJ. Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. Blood 2001;97:192-7
   PubMed Web of Science ®Google Scholar
• Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol 2006;6:836-48
   PubMed Web of Science ®Google Scholar
• Ehtesham M, Samoto K, Kabos P, et al. Treatment of intracranial glioma with in situ interferon-gamma and tumor necrosis factor-alpha gene transfer. Cancer Gene Ther 2002;9:925-34
   PubMed Web of Science ®Google Scholar
• Arko L, Katsyv I, Park GE, et al. Experimental approaches for the treatment of malignant gliomas. Pharmacol Ther 2010;128:1-36
   PubMed Web of Science ®Google Scholar
• Candolfi M, King GD, Yagiz K, et al. Plasmacytoid dendritic cells in the tumor microenvironment: immune targets for glioma therapeutics. Neoplasia 2012;14:757-70
   PubMed Web of Science ®Google Scholar
• Dix AR, Brooks WH, Roszman TL, et al. Immune defects observed in patients with primary malignant brain tumors. J Neuroimmunol 1999;100:216-32
   PubMed Web of Science ®Google Scholar
• Mahaley MS Jr, Brooks WH, Roszman TL, et al. Immunobiology of primary intracranial tumors. Part 1: studies of the cellular and humoral general immune competence of brain-tumor patients. J Neurosurg 1977;46:467-76
   PubMed Web of Science ®Google Scholar
• Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002;8:793-800
   PubMed Web of Science ®Google Scholar
• Morioka J, Kajiwara K, Yoshikawa K, et al. Adenovirus-mediated gene transfer of B7.1 induces immunological anti-tumor effects in a murine brain tumor. J Neurooncol 2002;60:13-23
   PubMed Web of Science ®Google Scholar
• Ino Y, Saeki Y, Fukuhara H, et al. Triple combination of oncolytic herpes simplex virus-1 vectors armed with interleukin-12, interleukin-18, or soluble B7-1 results in enhanced antitumor efficacy. Clin Cancer Res 2006;12:643-52
   PubMed Web of Science ®Google Scholar
• Chen B, Timiryasova TM, Haghighat P, et al. Low-dose vaccinia virus-mediated cytokine gene therapy of glioma. J Immunother 2001;24:46-57
   PubMed Web of Science ®Google Scholar
• Jean WC, Spellman SR, Wallenfriedman MA, et al. Interleukin-12-based immunotherapy against rat 9L glioma. Neurosurgery 1998;42:850-6; discussion 856-857
   PubMed Web of Science ®Google Scholar
• Parker JN, Gillespie GY, Love CE, et al. Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors. Proc Natl Acad Sci USA 2000;97:2208-13
   PubMed Web of Science ®Google Scholar
• Liu Y, Ehtesham M, Samoto K, et al. In situ adenoviral interleukin 12 gene transfer confers potent and long-lasting cytotoxic immunity in glioma. Cancer Gene Ther 2002;9:9-15
   PubMed Web of Science ®Google Scholar
• Ryu CH, Park SH, Park SA, et al. Gene therapy of intracranial glioma using interleukin 12-secreting human umbilical cord blood-derived mesenchymal stem cells. Hum Gene Ther 2011;22:733-43
   PubMed Web of Science ®Google Scholar
• Fischer U, Steffens S, Frank S, et al. Mechanisms of thymidine kinase/ganciclovir and cytosine deaminase/5-fluorocytosine suicide gene therapy-induced cell death in glioma cells. Oncogene 2005;24:1231-43
   PubMed Web of Science ®Google Scholar
• Tang D, Kang R, Coyne CB, et al. PAMPs and DAMPs: signal 0s that spur autophagy and immunity. Immunol Rev 2012;249:158-75
   PubMed Web of Science ®Google Scholar
• Ali S, King GD, Curtin JF, et al. Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model. Cancer Res 2005;65:7194-204
   PubMed Web of Science ®Google Scholar
• King GD, Muhammad AK, Curtin JF, et al. Flt3L and TK gene therapy eradicate multifocal glioma in a syngeneic glioblastoma model. Neuro Oncol 2008;10:19-31
   PubMed Web of Science ®Google Scholar
• King GD, Muhammad AK, Larocque D, et al. Combined Flt3L/TK gene therapy induces immunological surveillance which mediates an immune response against a surrogate brain tumor neoantigen. Mol Ther 2011;19:1793-801
   PubMed Web of Science ®Google Scholar
• Puntel M, Muhammad AK, Candolfi M, et al. A novel bicistronic high-capacity gutless adenovirus vector that drives constitutive expression of herpes simplex virus type 1 thymidine kinase and tet-inducible expression of Flt3L for glioma therapeutics. J Virol 2010;84:6007-17
   PubMed Web of Science ®Google Scholar
• Mineharu Y, King GD, Muhammad AK, et al. Engineering the brain tumor microenvironment enhances the efficacy of dendritic cell vaccination: implications for clinical trial design. Clin Cancer Res 2011;17:4705-18
   PubMed Web of Science ®Google Scholar
• Dent P, Yacoub A, Hamed HA, et al. MDA-7/IL-24 as a cancer therapeutic: from bench to bedside. Anticancer Drugs 2010;21:725-31
   PubMed Web of Science ®Google Scholar
• Emdad L, Lebedeva IV, Su ZZ, et al. Historical perspective and recent insights into our understanding of the molecular and biochemical basis of the antitumor properties of mda-7/IL-24. Cancer Biol Ther 2009;8:391-400
   PubMed Web of Science ®Google Scholar
• Yacoub A, Mitchell C, Lebedeva IV, et al. mda-7 (IL-24) Inhibits growth and enhances radiosensitivity of glioma cells in vitro via JNK signaling. Cancer Biol Ther 2003;2:347-53
   PubMed Web of Science ®Google Scholar
• Yacoub A, Mitchell C, Lister A, et al. Melanoma differentiation-associated 7 (interleukin 24) inhibits growth and enhances radiosensitivity of glioma cells in vitro and in vivo. Clin Cancer Res 2003;9:3272-81
   PubMed Web of Science ®Google Scholar
• Hamed HA, Yacoub A, Park MA, et al. Inhibition of multiple protective signaling pathways and Ad.5/3 delivery enhances mda-7/IL-24 therapy of malignant glioma. Mol Ther 2010;18:1130-42
   PubMed Web of Science ®Google Scholar
• Hamed HA, Yacoub A, Park MA, et al. Histone deacetylase inhibitors interact with melanoma differentiation associated-7/interleukin-24 to kill primary human glioblastoma cells. Mol Pharmacol 2013;84:171-81
   Google Scholar
• Trask TW, Trask RP, Aguilar-Cordova E, et al. Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors. Mol Ther 2000;1:195-203
   PubMed Web of Science ®Google Scholar
• Germano IM, Fable J, Gultekin SH, et al. Adenovirus/herpes simplex-thymidine kinase/ganciclovir complex: preliminary results of a phase I trial in patients with recurrent malignant gliomas. J Neurooncol 2003;65:279-89
   PubMed Web of Science ®Google Scholar
• Sandmair AM, Loimas S, Puranen P, et al. Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses. Hum Gene Ther 2000;11:2197-205
   PubMed Web of Science ®Google Scholar
• Smitt PS, Driesse M, Wolbers J, et al. Treatment of relapsed malignant glioma with an adenoviral vector containing the herpes simplex thymidine kinase gene followed by ganciclovir. Mol Ther 2003;7:851-8
   PubMed Web of Science ®Google Scholar
• Smith JG, Raper SE, Wheeldon EB, et al. Intracranial administration of adenovirus expressing HSV-TK in combination with ganciclovir produces a dose-dependent, self-limiting inflammatory response. Hum Gene Ther 1997;8:943-54
   PubMed Web of Science ®Google Scholar
• Eck SL, Alavi JB, Alavi A, et al. Treatment of advanced CNS malignancies with the recombinant adenovirus H5.010RSVTK: a phase I trial. Hum Gene Ther 1996;7:1465-82
   PubMed Web of Science ®Google Scholar
• Clinicaltrials.gov. Combined Cytotoxic and Immune-Stimulatory Therapy for Glioma (NCT01811992). Available from: www.clinicaltrials.gov US National Institutes of Health 2013
   Google Scholar
• Lang FF, Bruner JM, Fuller GN, et al. Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J Clin Oncol 2003;21:2508-18
   PubMed Web of Science ®Google Scholar
• Chiocca EA, Smith KM, McKinney B, et al. A phase I trial of Ad.hIFN-beta gene therapy for glioma. Mol Ther 2008;16:618-26
   PubMed Web of Science ®Google Scholar
• Chiocca EA, Abbed KM, Tatter S, et al. A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Mol Ther 2004;10:958-66
   PubMed Web of Science ®Google Scholar
• Edwards SJ, Dix BR, Myers CJ, et al. Evidence that replication of the antitumor adenovirus ONYX-015 is not controlled by the p53 and p14(ARF) tumor suppressor genes. J Virol 2002;76:12483-90
   PubMed Web of Science ®Google Scholar
• Hitt MM, Graham FL. Adenovirus vectors for human gene therapy. Adv Virus Res 2000;55:479-505
   PubMed Web of Science ®Google Scholar
• Graham FL. Adenovirus vectors for high-efficiency gene transfer into mammalian cells. Immunol Today 2000;21:426-8
   PubMedGoogle Scholar
• Graham FL, van der Eb AJ. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology 1973;52:456-67
   PubMed Web of Science ®Google Scholar
• Maguire AM, Simonelli F, Pierce EA, et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 2008;358:2240-8
   PubMed Web of Science ®Google Scholar
• Biffi A, Montini E, Lorioli L, et al. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science 2013;341:1233158
   PubMed Web of Science ®Google Scholar
• Aiuti A, Biasco L, Scaramuzza S, et al. Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science 2013;341:1233151
   PubMed Web of Science ®Google Scholar
• Westphal M, Yla-Herttuala S, Martin J, et al. Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): a randomised, open-label, phase 3 trial. Lancet Oncol 2013;14:823-33
   PubMed Web of Science ®Google Scholar
• Lowenstein PR. Immunology of viral-vector-mediated gene transfer into the brain: an evolutionary and developmental perspective. Trends Immunol 2002;23:23-30
   PubMed Web of Science ®Google Scholar
• Lowenstein PR. Dendritic cells and immune responses in the central nervous system. Trends Immunol 2002;23:70
   PubMed Web of Science ®Google Scholar
• Larocque D, Sanderson NS, Bergeron J, et al. Exogenous fms-like tyrosine kinase 3 ligand overrides brain immune privilege and facilitates recognition of a neo-antigen without causing autoimmune neuropathology. Proc Natl Acad Sci USA 2010;107:14443-8
   PubMed Web of Science ®Google Scholar
• Clinicaltrials.gov. DNX-2401 (Formerly Known as Delta-24-RGD-4C) for Recurrent Malignant Gliomas (NCT00805376). Available from: www.clinicaltrials.gov US National Institutes of Health 2008
   Google Scholar
• Clinicaltrials.gov. Safety Study of Replication-competent Adenovirus (Delta-24-rgd) in Patients With Recurrent Glioblastoma (NCT01582516). Available from: www.clinicaltrials.gov US National Institutes of Health 2012
   Google Scholar
• Clinicaltrials.gov. Phase 1b Study of AdV-tk + Valacyclovir Combined With Radiation Therapy for Malignant Gliomas (NCT00751270). Available from: www.clinicaltrials.gov US National Institutes of Health 2008
   Google Scholar
• Clinicaltrials.gov. Phase 2a Study of AdV-tk With Standard Radiation Therapy for Malignant Glioma (BrTK02) (NCT00589875). Available from: www.clinicaltrials.gov US National Institutes of Health 2007
   Google Scholar